Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, United States.
Vaccine. 2010 Apr 9;28(17):2999-3007. doi: 10.1016/j.vaccine.2010.02.006. Epub 2010 Feb 17.
Using a gp120 envelope glycoprotein from the JR-FL strain of human immunodeficiency virus-1 (HIV-1) as a model antigen, the goal of the current study was to evaluate the level and quality of antibody responses elicited by different prime-boost vaccination regimens (protein only, DNA only, DNA plus protein) in rabbits. Our data demonstrated that incorporating DNA immunization as a prime in a heterologous prime-boost regimen was able to elicit a more diverse and conformational epitope profile, higher antibody avidity, and improved neutralizing activity than immunization with only protein. Additionally, this improved neutralizing activity was observed in spite of similar antibody specificities and avidities seen when only DNA vaccination was used, providing additional evidence that the use of a combination immunization regimen increases the protective antibody response. Insights gained from the current study confirmed that the heterologous DNA prime-protein boost approach is effective in eliciting not only high level but also improved quality of antigen-specific antibody responses, and thus may offer a new technology platform to develop better and safer subunit vaccines.
利用人类免疫缺陷病毒 1(HIV-1)JR-FL 株的 gp120 包膜糖蛋白作为模型抗原,本研究旨在评估不同初免-加强免疫方案(仅蛋白、仅 DNA、DNA 加蛋白)在兔中诱导的抗体反应水平和质量。我们的数据表明,将 DNA 免疫作为异源初免-加强免疫方案的初免,可以诱导出更广泛和构象表位谱、更高的抗体亲和力和改善的中和活性,优于仅用蛋白免疫。此外,尽管仅用 DNA 接种时观察到相似的抗体特异性和亲和力,但仍观察到这种改善的中和活性,这提供了额外的证据表明,使用联合免疫方案可增加保护性抗体反应。本研究获得的见解证实,异源 DNA 初免-蛋白加强免疫方法不仅能有效诱导高水平,还能改善抗原特异性抗体反应的质量,因此可能为开发更好、更安全的亚单位疫苗提供新的技术平台。